Therapix Biosciences, a specialty clinical-stage pharmaceutical company specialising in the development of cannabinoid-based drugs, has signed a sublicense agreement for Yissum Research Development Company of the Hebrew University nasal drug delivery tech
University of Alberta scientists have pulled into the lead in a race to use nanomachines for improved disease detection and drug delivery in patients. In a study published in Nature Communications, the researchers describe the creation of synthetic DNA mo